Filing Flows › Comparisons › NKTR vs EVMN
Nektar Therapeutics vs Evommune: NKTR and EVMN compared
Nektar Therapeutics is the larger company: $10.1M of revenue in its latest quarter (Q2 2026) against $10.0M for Evommune (Q3 2025). Evommune is more profitable, with an operating margin of -133.3% against -417.9%.
Where the money goes: NKTR and EVMN
Nektar Therapeutics (NKTR) · Q2 2026
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.
Evommune (EVMN) · Q3 2025
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
| Nektar Therapeutics (NKTR) | Evommune (EVMN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2025 |
| Revenue | $10.1M | $10.0M |
| Revenue growth, Y/Y | -9% | — |
| Operating margin | -417.9% | -133.3% |
| Net earnings | −$40.6M | −$12.5M |
| Net margin | -401.0% | -124.8% |
| Operating cash flow | −$75.8M | −$9.6M |
Questions
Which is bigger, Nektar Therapeutics or Evommune?
Nektar Therapeutics is the larger company: $10.1M of revenue in its latest quarter (Q2 2026) against $10.0M for Evommune (Q3 2025).
Is Nektar Therapeutics or Evommune growing faster?
Evommune is more profitable, with an operating margin of -133.3% against -417.9%.
More: Nektar Therapeutics earnings · how Nektar Therapeutics makes money · Evommune earnings · how Evommune makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Dec 11, 2025). Fiscal quarters can end on different dates. Not investment advice.